Literature DB >> 6371822

Second antibody clearance of radiolabeled antibody in cancer radioimmunodetection.

R M Sharkey, F J Primus, D M Goldenberg.   

Abstract

The imaging of tumors using radiolabeled antibodies previously has required the implementation of computer-assisted subtraction techniques to reduce background radioactivity. A decrease in radioactivity in the blood of hamsters bearing human colonic tumor xenografts has been achieved by administering a second antibody directed against a radiolabeled primary antibody to carcinoembryonic antigen (CEA). This method was found to reduce the level of blood radioactivity by a factor of 4 within 2 hr after injection of the second antibody and to enhance tumor/nontumor ratios within 24 hr. Unlike liposomally entrapped second antibody, the primary anti-CEA antibody did not show increased accretion of radioactivity in the liver, spleen, or other major organs. These results suggest that administration of a second antibody alone may improve tumor imaging with a radiolabeled antitumor antibody.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6371822      PMCID: PMC345167          DOI: 10.1073/pnas.81.9.2843

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  12 in total

1.  The in vivo localization of anti-Wagner-osteogenic-sarcoma antibodies.

Authors:  D PRESSMAN; L KORNGOLD
Journal:  Cancer       Date:  1953-05       Impact factor: 6.860

2.  Carcinoembryonic antigen present in human colonic neoplasms serially propagated in hamsters.

Authors:  D M Goldenberg; H J Hansen
Journal:  Science       Date:  1972-03-10       Impact factor: 47.728

3.  Improved radioimmunodetection of tumours using second antibody.

Authors:  A R Bradwell; A Vaughan; D S Fairweather; P W Dykes
Journal:  Lancet       Date:  1983-01-29       Impact factor: 79.321

4.  Binding of immunoglobulin G to phospholipid vesicles by sonication.

Authors:  L Huang; S J Kennel
Journal:  Biochemistry       Date:  1979-05-01       Impact factor: 3.162

Review 5.  New aspects of liposomes.

Authors:  D A Tyrrell; T D Heath; C M Colley; B E Ryman
Journal:  Biochim Biophys Acta       Date:  1976-12-14

6.  Liposomally entrapped second antibody improves tumour imaging with radiolabelled (first) antitumour antibody.

Authors:  R H Begent; P A Keep; A J Green; F Searle; K D Bagshawe; R F Jewkes; B E Jones; G M Barratt; B E Ryman
Journal:  Lancet       Date:  1982-10-02       Impact factor: 79.321

7.  Carcinoembryonic antigen radioimmunodetection in the evaluation of colorectal cancer and in the detection of occult neoplasms.

Authors:  D M Goldenberg; E E Kim; S J Bennett; M O Nelson; F H Deland
Journal:  Gastroenterology       Date:  1983-03       Impact factor: 22.682

8.  Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning.

Authors:  D M Goldenberg; F DeLand; E Kim; S Bennett; F J Primus; J R van Nagell; N Estes; P DeSimone; P Rayburn
Journal:  N Engl J Med       Date:  1978-06-22       Impact factor: 91.245

9.  Human chorionic gonadotropin radioantibodies in the radioimmunodetection of cancer and for disclosure of occult metastases.

Authors:  D M Goldenberg; E E Kim; F H DeLand
Journal:  Proc Natl Acad Sci U S A       Date:  1981-12       Impact factor: 11.205

10.  Localization of GW-39 human tumors in hamsters by affinity-purified antibody to carcinoembryonic antigen.

Authors:  F J Primus; R Macdonald; D M Goldenberg; H J Hansen
Journal:  Cancer Res       Date:  1977-05       Impact factor: 12.701

View more
  13 in total

Review 1.  Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy.

Authors:  Robert M Sharkey; Edmund A Rossi; William J McBride; Chien-Hsing Chang; David M Goldenberg
Journal:  Semin Nucl Med       Date:  2010-05       Impact factor: 4.446

2.  Second antibody for improvement of antibody imaging: liposome-entrapped and free preparations in animal and human studies.

Authors:  H J Begent; K A Chester; K D Bagshawe; P A Keep; F Searle; J Boden; G M Barratt; A J Green; S J Riggs; D F Woodrow
Journal:  Clin Exp Immunol       Date:  1989-11       Impact factor: 4.330

3.  Adding a clearing agent to pretargeting does not lower the tumor accumulation of the effector as predicted.

Authors:  Guozheng Liu; Shuping Dou; Xiangji Chen; Ling Chen; Xinrong Liu; Mary Rusckowski; Donald J Hnatowich
Journal:  Cancer Biother Radiopharm       Date:  2010-12       Impact factor: 3.099

4.  Avidin chase reduces side effects of radioimmunotherapy in nude mice bearing human colon carcinoma.

Authors:  Gui-Ping Li; Yong-Xian Wang; Kai Huang; Hui Zhang; Chun-Fu Zhang
Journal:  World J Gastroenterol       Date:  2005-04-07       Impact factor: 5.742

5.  Metabolizable 111In chelate conjugated anti-idiotype monoclonal antibody for radioimmunodetection of lymphoma in mice.

Authors:  M K Haseman; D A Goodwin; C F Meares; M S Kaminski; T G Wensel; M J McCall; R Levy
Journal:  Eur J Nucl Med       Date:  1986

Review 6.  Addressing challenges of heterogeneous tumor treatment through bispecific protein-mediated pretargeted drug delivery.

Authors:  Qi Yang; Christina L Parker; Justin D McCallen; Samuel K Lai
Journal:  J Control Release       Date:  2015-09-25       Impact factor: 9.776

Review 7.  Current status of cancer imaging with radiolabeled antibodies.

Authors:  D M Goldenberg
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

8.  Antibody-directed enzyme prodrug therapy (ADEPT). A three-phase study in ovarian tumor xenografts.

Authors:  S K Sharma; J A Boden; C J Springer; P J Burke; K D Bagshawe
Journal:  Cell Biophys       Date:  1994

9.  Syngeneic anti-idiotypic antibodies eliminate excess radiolabeled idiotypes at experimental radioimmunolocalization.

Authors:  A Ullén; K Riklund Ahlström; R Makiya; T Stigbrand
Journal:  Cell Biophys       Date:  1995-08

10.  Clearance of circulating radio-antibodies using streptavidin or second antibodies in a xenograft model.

Authors:  D Marshall; R B Pedley; J A Boden; R Boden; R H Begent
Journal:  Br J Cancer       Date:  1994-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.